Comment of an Expert Group of the Paul-Ehrlich-Society for Chemotherapy on the benefit assessment of fidaxomicin for treatment of Clostridium difficile infections
Main Authors: | Kresken, Michael, von Müller, Lutz, Grabein, Béatrice, Herrmann, Mathias, Höffken, Gert, Hoerauf, Achim, Kern, Peter, Pletz, Mathias W., Reisinger, Emil, Cornely, Oliver A., Groll, Andreas H. |
---|---|
Format: | Article |
Language: | English |
Published: |
German Medical Science GMS Publishing House
2013-11-01
|
Series: | GMS Infectious Diseases |
Online Access: | http://www.egms.de/static/en/journals/id/2013-1/id000007.shtml |
Similar Items
-
Clostridium difficile infections and fidaxomicin treatment
by: Laura Fascio Pecetto
Published: (2014-12-01) -
Fidaxomicin - the new drug for Clostridium difficile infection
by: Chetana Vaishnavi
Published: (2015-01-01) -
Recurrent Clostridium difficile colitis in elderly: the role of fidaxomicin
by: Francesco Artom, et al.
Published: (2014-12-01) -
Clostridium difficile colitis in an immunocompromised patient treated with fidaxomicin
by: Marcello Feasi
Published: (2015-05-01) -
Emerging therapies for Clostridium difficile infection – focus on fidaxomicin
by: Chaparro-Rojas F, et al.
Published: (2013-06-01)